Pendal Group Ltd acquired a new stake in Incyte Co. (NASDAQ:INCY) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 26,672 shares of the biopharmaceutical company’s stock, valued at approximately $2,266,000.

A number of other large investors have also recently bought and sold shares of INCY. Bremer Bank National Association purchased a new position in Incyte in the 1st quarter valued at about $31,000. Financial Gravity Wealth Inc. purchased a new position in Incyte in the 1st quarter valued at about $51,000. Pearl River Capital LLC bought a new position in shares of Incyte during the first quarter worth about $68,000. Quadrant Capital Group LLC lifted its position in shares of Incyte by 555.1% during the first quarter. Quadrant Capital Group LLC now owns 963 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 816 shares during the last quarter. Finally, Enterprise Financial Services Corp lifted its position in shares of Incyte by 1,199.1% during the first quarter. Enterprise Financial Services Corp now owns 1,481 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 1,367 shares during the last quarter. 90.47% of the stock is owned by institutional investors.

In other Incyte news, Director Paul A. Friedman sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $82.69, for a total value of $8,269,000.00. Following the sale, the director now owns 277,597 shares in the company, valued at $22,954,495.93. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jean Jacques Bienaime sold 1,724 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $85.07, for a total transaction of $146,660.68. Following the completion of the sale, the director now owns 277,597 shares in the company, valued at approximately $23,615,176.79. The disclosure for this sale can be found here. In the last quarter, insiders have sold 116,040 shares of company stock worth $9,627,376. 17.10% of the stock is owned by company insiders.

Several brokerages have recently commented on INCY. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Incyte in a research report on Monday, June 17th. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $91.00 price target on shares of Incyte in a research report on Wednesday, July 31st. Nomura increased their price target on shares of Incyte from $100.00 to $111.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Credit Suisse Group began coverage on shares of Incyte in a research report on Monday, May 20th. They set a “neutral” rating and a $75.00 price target on the stock. Finally, Leerink Swann set a $90.00 price target on shares of Incyte and gave the stock a “hold” rating in a research report on Wednesday, July 31st. Twelve equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $89.67.

INCY traded down $0.15 on Thursday, hitting $80.91. 11,617 shares of the company’s stock were exchanged, compared to its average volume of 1,175,418. The firm has a market capitalization of $17.74 billion, a price-to-earnings ratio of 98.27 and a beta of 1.12. Incyte Co. has a twelve month low of $57.00 and a twelve month high of $89.30. The company’s fifty day simple moving average is $82.50. The company has a current ratio of 5.61, a quick ratio of 5.59 and a debt-to-equity ratio of 0.02.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.37. The firm had revenue of $529.93 million for the quarter, compared to analyst estimates of $498.57 million. Incyte had a net margin of 15.25% and a return on equity of 17.10%. Incyte’s quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 earnings per share. On average, equities analysts expect that Incyte Co. will post 1.98 EPS for the current fiscal year.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Featured Article: Technical Indicators – What is a Golden Cross?

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.